{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:31Z","timestamp":1791646471029,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.rmed.2021.106728","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:09:09Z","timestamp":1641035349000},"page":"106728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Bronchiectasis and inhaled tobramycin: A literature review"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-442X","authenticated-orcid":false,"given":"J. Stuart","family":"Elborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Ballmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm A.W.M.","family":"Tiddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Murris-Espin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 M.","family":"Cantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2021.106728_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","article-title":"Clinical phenotypes in adult patients with bronchiectasis","volume":"47","author":"Aliberti","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2021.106728_bib2","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2021.106728_bib3","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.rmed.2021.106728_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12924","article-title":"Suspecting non-cystic fibrosis bronchiectasis: what the busy primary care clinician needs to know","volume":"71","author":"Maselli","year":"2017","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.rmed.2021.106728_bib8","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1016\/S2214-109X(19)30311-0","article-title":"Time to acknowledge, address, and take action against bronchiectasis","volume":"7","author":"Chotirmall","year":"2019","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2021.106728_bib10","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1183\/13993003.00954-2015","article-title":"Bronchiectasis in Germany: a population-based estimation of disease prevalence","volume":"46","author":"Ringshausen","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2021.106728_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron. Respir. Dis."},{"issue":"5","key":"10.1016\/j.rmed.2021.106728_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1513\/AnnalsATS.201511-740PS","article-title":"Bronchiectasis in China","volume":"13","author":"Lin","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12890-020-1050-0","article-title":"Prevalence and incidence of bronchiectasis in Italy","volume":"20","author":"Aliberti","year":"2020","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"10.1016\/j.rmed.2021.106728_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1183\/09031936.00212114","article-title":"Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis","volume":"46","author":"Garratt","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12931-017-0691-x","article-title":"Neutrophil elastase in bronchiectasis","volume":"18","author":"Gramegna","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2021.106728_bib16","first-page":"6","article-title":"Inflammation: a two-edged sword--the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur. J. Respir. Dis. Suppl."},{"issue":"10150","key":"10.1016\/j.rmed.2021.106728_bib17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2021.106728_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.cmet.2020.04.017","article-title":"Pseudomonas aeruginosa utilizes host-derived itaconate to redirect its metabolism to promote biofilm formation","volume":"31","author":"Riquelme","year":"2020","journal-title":"Cell Metabol."},{"key":"10.1016\/j.rmed.2021.106728_bib19","series-title":"Medical Microbiology","article-title":"Pseudomonas","author":"Iglewski","year":"1996"},{"issue":"5","key":"10.1016\/j.rmed.2021.106728_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1183\/09031936.06.00074605","article-title":"The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis","volume":"28","author":"Davies","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2021.106728_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1183\/09031936.00097014","article-title":"Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function","volume":"44","author":"Nair","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2021.106728_bib22","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1183\/09031936.00076214","article-title":"Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells","volume":"45","author":"Trinh","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0974-777X.150885","article-title":"Influence of Pseudomonas aeruginosa on exacerbation in patients with bronchiectasis","volume":"7","author":"Chawla","year":"2015","journal-title":"J. Global Infect. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2021.106728_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1378\/chest.08-0776","article-title":"Bronchiectasis","volume":"134","author":"O'Donnell","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2021.106728_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/2225-6482.184910","article-title":"Exacerbations of bronchiectasis in adults","volume":"3","author":"Redondo","year":"2016","journal-title":"Community Acquir. Infect."},{"issue":"suppl 1","key":"10.1016\/j.rmed.2021.106728_bib26","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British thoracic society bronchiectasis (non-CF) guideline group. British thoracic society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"suppl 1","key":"10.1016\/j.rmed.2021.106728_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British thoracic society guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"issue":"2 Pt 1","key":"10.1016\/j.rmed.2021.106728_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2021.106728_bib29","first-page":"1420","article-title":"A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis","volume":"127","author":"Scheinberg","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non\u2013cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.rmed.2021.106728_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000438490","article-title":"Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"90","author":"Orriols","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2021.106728_bib32","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"iBEST-1 Trial Team. Efficacy and safety of TOBI Podhaler\u00ae in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"14","key":"10.1016\/j.rmed.2021.106728_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.21037\/atm.2019.06.62","article-title":"Quality of life in patients with bronchiectasis: a 2-year longitudinal study","volume":"7","author":"Magge","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"7","key":"10.1016\/j.rmed.2021.106728_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2021.106728_bib35","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.rmed.2021.106728_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bcp.13439","article-title":"Adverse effects of a single dose of gentamicin in adults: a systematic review","volume":"84","author":"Hayward","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.rmed.2021.106728_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/2229-5151.79277","article-title":"Risk factors for aminoglycoside-associated nephrotoxicity in surgical intensive care unit patients","volume":"1","author":"Gerlach","year":"2011","journal-title":"Int. J. Crit. Illn. Inj. Sci."},{"issue":"12","key":"10.1016\/j.rmed.2021.106728_bib39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/qjmed\/hcp143","article-title":"Gentamicin-associated acute kidney injury","volume":"102","author":"Selby","year":"2009","journal-title":"QJM"},{"issue":"7","key":"10.1016\/j.rmed.2021.106728_bib40","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1128\/AAC.01430-08","article-title":"Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units","volume":"53","author":"Oliveira","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"10.1016\/j.rmed.2021.106728_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.heares.2011.05.008","article-title":"New developments in aminoglycoside therapy and ototoxicity","volume":"281","author":"Xie","year":"2011","journal-title":"Hear. Res."},{"issue":"4","key":"10.1016\/j.rmed.2021.106728_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/cpt.603","article-title":"Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies","volume":"101","author":"Lanvers-Kaminsky","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2021.106728_bib44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1513\/AnnalsATS.201310-352OC","article-title":"Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis","volume":"11","author":"Nick","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.rmed.2021.106728_bib45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jcf.2016.12.003","article-title":"Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis","volume":"16","author":"Nichols","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"10","key":"10.1016\/j.rmed.2021.106728_bib46","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1128\/AAC.00372-10","article-title":"Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model","volume":"54","author":"Tr\u00e9-Hardy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2021.106728_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/CCRPM.S10592","article-title":"Tobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"7","author":"Lam","year":"2013","journal-title":"Clin. Med. Insights Circulatory, Respir. Pulm. Med."},{"issue":"5","key":"10.1016\/j.rmed.2021.106728_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1753465817691239","article-title":"Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence","volume":"11","author":"Hamed","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2021.106728_bib49","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2018.08.014","article-title":"Defining antimicrobial resistance in cystic fibrosis","volume":"17","author":"Kidd","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2021.106728_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118454","article-title":"Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?","volume":"10","author":"Bos","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/514631","article-title":"Microbiology of sputum from patients at cystic fibrosis centers in the United States","volume":"27","author":"Burns","year":"1998","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib53","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2021.106728_bib54","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2021.106728_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.rmed.2021.106728_bib56","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121004364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121004364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:26:19Z","timestamp":1760617579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611121004364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":54,"alternative-id":["S0954611121004364"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106728","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bronchiectasis and inhaled tobramycin: A literature review","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106728"}}